Glass Lewis Backs Pacira Board in Proxy Battle Against Activist DOMA Perpetual
PCRX sits 26% above its 52-week low of $18.8 on light trading volume (0.4× avg).
Summary
Pacira BioSciences announced that Glass Lewis, a leading independent proxy advisory firm, recommended shareholders vote for all of Pacira's director nominees and against those proposed by activist investor DOMA Perpetual Capital Management, significantly bolstering the incumbent board's position in the ongoing proxy battle.
Key Events · Corporate Governance and Compliance · PCRX
-
Glass Lewis Recommends Pacira's Nominees
Leading independent proxy advisory firm Glass Lewis & Co., LLC has recommended that Pacira stockholders vote "FOR" each of Pacira's three director nominees and "AGAINST" all three of DOMA Perpetual Capital Management LLC's nominees on the BLUE proxy card.
-
Endorsement of 5x30 Strategy
Glass Lewis concluded that Pacira has an actionable plan (the 5x30 strategy) designed to deliver substantial stockholder value by 2030, noting the Company's one-year total stockholder return of 37% for calendar year 2025.
-
Critique of Activist Nominees
Glass Lewis stated that DOMA Perpetual has not presented sufficiently compelling cause to scupper the 5x30 Plan and that DOMA's nominees do not evidently possess the skills necessary to effectively execute their proposed plan.
-
Upcoming Annual Meeting
The recommendation comes ahead of the Company's 2026 Annual Meeting of Stockholders on June 9, 2026, where the contested board election will be decided.
Analysis · PCRX · Life Sciences
This filing is highly important because a positive recommendation from Glass Lewis, a leading independent proxy advisory firm, can significantly influence institutional investors and other shareholders in the ongoing proxy contest. Glass Lewis's endorsement of Pacira's current board and its "5x30 strategy," coupled with its critique of the activist investor DOMA Perpetual's nominees and plans, provides strong validation for the incumbent management. This development could be a decisive factor in the upcoming annual meeting on June 9, 2026, impacting the company's future leadership and strategic direction.
At the time of this filing, PCRX was trading at $23.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $931.5M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.